Review compares outcomes, safety for once-weekly GLP-1RAs
(HealthDay)—Cardiometabolic outcomes and safety vary among different once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) treatments, according to a review published online Dec. 8 in the Annals of Internal Medicine.
Dec 8, 2015
0
1